London-based PE firm CapVest has bought a 70% stake in German pharma company Stada, in Europe’s biggest healthcare deal of 2025 so far. Bain Capital and Cinven, the company’s joint PE owners since 2017, will continue to hold the remaining 30%.
US PE firm Sycamore Partners has completed its $10 billion take-private of Walgreens Boots Alliance (WBA), a US healthcare, pharmacy and retail company that owns UK pharmacy chain Boots. Sycamore has decided to separate off Boots, as expected.
Eli Lilly has increased their UK price for the weight-loss injection Mounjaro by 170% to align with prices in other high-income countries. This move follows Trump’s mandate on pharmaceuticals to raise prices abroad to make them more affordable for U.S. consumers.
With France facing persistent medicine shortages and heightened political focus on healthcare sovereignty, the generic pharmaceuticals sector is drawing increased attention from private investors and policymakers alike. Growing interest in maintaining domestic production and securing supply chains has positioned French generics as both a strategic asset and a market opportunity.
Last month, HBI covered how EU tariff negotiations would affect pharma prices. At that time, Donald Trump had been threatening a 50% tariff on all EU imports and a 200% tariff on pharmaceutical imports, creating much uncertainty around the final state of the trade deal. On Tuesday, however, Trump told CNBC that while the tariffs on pharmaceuticals may be “small” initially, in a year's time they will be increased to 150% and then 250%.
Earlier this month reports showed Colombia’s already-struggling health system seeing units in hospitals in capital Bogotá being forced to close down to be able to continue other types of care services. In recent months patients have also been denied access to medications and health services, with the financial crisis facing the healthcare sector in the country still unfolding.
It has been claimed GLP-1 drugs like Ozempic and Mounjaro could be available to NHS patients over the counter at pharmacies, according to news reports.
Large scale healthcare services M&A has been mostly on hold in Europe for almost three years now. Despite all the economic and geopolitical uncertainty the world is currently facing, 2025 will probably see more activity.
Gerresheimer AG, a German maker of packaging for drugs and cosmetics, has confirmed it is in discussions with private equity investors about a potential takeover offer.
Pharmacy leaders have issued a new warning over the online sale of weight loss jabs (GLP-1s) and patient safety amid predictions of a boom in demand for the drugs this year.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.